3-(2,4-difluorophenoxy)pyridine-4-carboxylic acid | 1007571-75-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(2,4-difluorophenoxy)pyridine-4-carboxylic acid
• 英文别名: 3-(2,4-difluoro-phenoxy)-pyridazine-4-carboxylic acid；3-(2,4-Difluorophenoxy)pyridazine-4-carboxylic acid
• CAS: 1007571-75-6
• 化学式: C₁₁H₆F₂N₂O₃
• mdl: MFCD23433794
• 分子量: 252.177
• InChiKey: SVWQGSGOVWPORJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.3
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  [4-溴-3-(3,5-二氰基苯氧基)-2-氟苯基]乙酸乙酯 、 3-(2,4-difluorophenoxy)pyridine-4-carboxylic acid 在 N,N'-羰基二咪唑 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Design of Annulated Pyrazoles as Inhibitors of HIV-1 Reverse Transcriptase

  摘要：

  Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are recommended components of preferred combination antiretroviral therapies used for the treatment of HIV. These regimens are extremely effective in suppressing virus replication. Structure-based optimization of diaryl ether inhibitors led to the discovery of a new series of pyrazolo[3,4-c]pyridazine NNRTIs that bind the reverse transcriptase enzyme of human immunodeficiency virus-1 (HIV-RT) in an expanded volume relative to most other inhibitors in this class.The binding mode maintains the beta13 and beta14 strands bearing Pro236 in a position similar to that in the unliganded reverse transcriptase structure, and the distribution of interactions creates the opportunity for substantial resilience to single point mutations. Several pyrazolopyridazine NNRTIs were found to be highly effective against wild-type and NNRTI-resistant viral strains in cell culture.

  DOI：

  10.1021/jm800527x
• 作为产物：
  描述：

  在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 0.25h， 生成 3-(2,4-difluorophenoxy)pyridine-4-carboxylic acid
  参考文献：
  名称：

  Design of Annulated Pyrazoles as Inhibitors of HIV-1 Reverse Transcriptase

  摘要：

  Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are recommended components of preferred combination antiretroviral therapies used for the treatment of HIV. These regimens are extremely effective in suppressing virus replication. Structure-based optimization of diaryl ether inhibitors led to the discovery of a new series of pyrazolo[3,4-c]pyridazine NNRTIs that bind the reverse transcriptase enzyme of human immunodeficiency virus-1 (HIV-RT) in an expanded volume relative to most other inhibitors in this class.The binding mode maintains the beta13 and beta14 strands bearing Pro236 in a position similar to that in the unliganded reverse transcriptase structure, and the distribution of interactions creates the opportunity for substantial resilience to single point mutations. Several pyrazolopyridazine NNRTIs were found to be highly effective against wild-type and NNRTI-resistant viral strains in cell culture.

  DOI：

  10.1021/jm800527x

文献信息

• Non-nucleoside reverse transcriptase inhibitors
  申请人：Billedeau Roland Joseph

  公开号：US20080293664A1

  公开（公告）日：2008-11-27

  Compounds of formula I, wherein R 1 , R 2 , R 3 , R 4 , R a , X, X 1 , and Y are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

  式I的化合物，其中R1、R2、R3、R4、Ra、X、X1和Y如本文所定义或其药学上可接受的盐，能抑制HIV-1逆转录酶，并提供一种预防和治疗HIV-1感染以及治疗艾滋病和/或ARC的方法。本发明还涉及含有式I化合物的组合物，用于预防和治疗HIV-1感染以及治疗艾滋病和/或ARC。
• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：Billedeau Roland Joseph

  公开号：US20090170856A1

  公开（公告）日：2009-07-02

  Compounds of formula I, wherein R 1 , R 2 , R 3 , X 1 , X 2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV- 1 infections and the treatment of AIDS and/or ARC.

  式I化合物，其中R1、R2、R3、X1、X2和Ar如本文所定义，或其药学上可接受的盐，抑制HIV-1逆转录酶，并提供预防和治疗HIV-1感染以及治疗艾滋病和/或艾滋病相关复合征（ARC）的方法。本发明还涉及含有式I化合物的组合物，这些组合物对于预防和治疗HIV-1感染以及治疗艾滋病和/或ARC是有用的。
• NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
  申请人：Kennedy-Smith Joshua

  公开号：US20110059975A1

  公开（公告）日：2011-03-10

  The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A2 and R 1 , R 2 , R 3 , R 4a , R 4b , R 5 , R 6 , Ar, X 1 , X 2 , X 4 , X 4 and X 5 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

  本发明提供了一种用于治疗HIV感染、预防HIV感染或治疗艾滋病或ARC的化合物。本发明的化合物的公式为I，其中A为A2，R1、R2、R3、R4a、R4b、R5、R6、Ar、X1、X2、X4、X4和X5如本文所定义。本发明还揭示了使用上述化合物治疗HIV感染的方法和包含该化合物的药物组合物。
• US7713974B2
  申请人：——

  公开号：US7713974B2

  公开（公告）日：2010-05-11
• US8063064B2
  申请人：——

  公开号：US8063064B2

  公开（公告）日：2011-11-22